1. Home
  2. FUNC vs LYEL Comparison

FUNC vs LYEL Comparison

Compare FUNC & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FUNC

First United Corporation

HOLD

Current Price

$45.30

Market Cap

283.6M

Sector

Finance

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$13.81

Market Cap

320.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUNC
LYEL
Founded
1900
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
283.6M
320.1M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
FUNC
LYEL
Price
$45.30
$13.81
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.60
AVG Volume (30 Days)
19.9K
151.9K
Earning Date
04-20-2026
05-13-2026
Dividend Yield
2.80%
N/A
EPS Growth
19.68
N/A
EPS
1.90
N/A
Revenue
$18,426,000.00
$36,000.00
Revenue This Year
$13.05
N/A
Revenue Next Year
$6.56
$8,712.13
P/E Ratio
$23.88
N/A
Revenue Growth
4.01
N/A
52 Week Low
$33.54
$10.49
52 Week High
$46.30
$45.00

Technical Indicators

Market Signals
Indicator
FUNC
LYEL
Relative Strength Index (RSI) 54.63 48.32
Support Level $43.48 $11.87
Resistance Level $46.13 $14.14
Average True Range (ATR) 0.91 0.88
MACD -0.01 0.06
Stochastic Oscillator 66.12 30.87

Price Performance

Historical Comparison
FUNC
LYEL

About FUNC First United Corporation

First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: